Chengdu Kanghong Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company") held the 19th meeting of the 8th Board of Directors on June 2, 2026, and approved the proposal regarding the cancellation of certain stock appreciation rights under the 2023 Stock Appreciation Rights Incentive Plan. The Company will cancel 30,000 stock appreciation rights that have not yet been exercised.
- Relevant Approval Procedures
On December 5, 2023, the Company convened the 1st meeting of the 8th Board of Directors and approved the "2023 Stock Appreciation Rights Incentive Plan (Draft)" and its summary. The Company also approved the "2023 Stock Appreciation Rights Incentive Plan (Draft) Implementation Management Measures" and the "2023 Stock Appreciation Rights Incentive Plan (Draft) Subject List."